{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:37:53Z","timestamp":1790519873312,"version":"4.1.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,4,13]],"date-time":"2018-04-13T00:00:00Z","timestamp":1523577600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.00622","type":"journal-article","created":{"date-parts":[[2018,4,13]],"date-time":"2018-04-13T00:11:45Z","timestamp":1523578305000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":114,"title":["B Cell Modulation Strategies in Autoimmune Diseases: New Concepts"],"prefix":"10.3389","volume":"9","author":[{"given":"Philippe","family":"Musette","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean David","family":"Bouaziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,4,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1038\/ni833","article-title":"B cells regulate autoimmunity by provision of IL-10","volume":"3","author":"Fillatreau","year":"2002","journal-title":"Nat Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1146\/annurev-immunol-020711-074934","article-title":"Immune regulatory function of B cells","volume":"30","author":"Mauri","year":"2012","journal-title":"Annu Rev Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/j.1600-065X.2008.00661.x","article-title":"Regulatory B cells as inhibitors of immune responses and inflammation","volume":"224","author":"Bouaziz","year":"2008","journal-title":"Immunol Rev"},{"key":"B4","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/j.1600-065X.2010.00945.x","article-title":"B-cell targeted therapies in human autoimmune diseases: an updated perspective","volume":"237","author":"Townsend","year":"2010","journal-title":"Immunol Rev"},{"key":"B5","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/1741-7015-11-120","article-title":"Novel therapeutic agents in clinical development for systemic lupus erythematosus","volume":"11","author":"Jordan","year":"2013","journal-title":"BMC Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1084\/jem.177.3.679","article-title":"B lymphocytes in vivo fail to prime naive T cells but can stimulate antigen-experienced T lymphocytes","volume":"177","author":"Ronchese","year":"1993","journal-title":"J Exp Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/82717","article-title":"Reciprocal regulation of polarized cytokine production by effector B and T cells","volume":"1","author":"Harris","year":"2000","journal-title":"Nat Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"5133","DOI":"10.1073\/pnas.1215840110","article-title":"B cells promote inflammation in obesity and type 2 diabetes through regulation of T cell function and inflammatory cytokine profile","volume":"110","author":"Defuria","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1684\/ecn.2013.0327","article-title":"B cell-derived cytokines in diseases","volume":"24","author":"Hamze","year":"2013","journal-title":"Eur Cytokine Netw"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1084\/jem.20111675","article-title":"B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells","volume":"209","author":"Barr","year":"2012","journal-title":"J Exp Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2010-01-266668","article-title":"Am\u201cB\u201dvalent: anti CD20 antibodies unravel the dual role of B cells in immunopathogenesis","volume":"116","author":"Thaunat","year":"2010","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40744-015-0016-9","article-title":"Rituximab for rheumatoid arthritis","volume":"2","author":"Cohen","year":"2015","journal-title":"Rheumatol Ther"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1002\/eji.201040673","article-title":"IL10 produced by activated human B cells regulates CD4(+) T-cell activation in vitro","volume":"40","author":"Bouaziz","year":"2010","journal-title":"Eur J Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1182\/blood-2010-07-294249","article-title":"Characterization of a rare IL10-competent B-cell subset in humans that parallels mouse regulatory B10 cells","volume":"117","author":"Iwata","year":"2011","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.immuni.2009.11.009","article-title":"CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients","volume":"32","author":"Blair","year":"2010","journal-title":"Immunity"},{"key":"B20","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1182\/blood-2012-05-432575","article-title":"Defective regulatory B-cell compartment in patients with immune thrombocytopenia","volume":"120","author":"Li","year":"2012","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"173ra23","DOI":"10.1126\/scitranslmed.3005407","article-title":"CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH2 differentiation","volume":"5","author":"Flores-Borja","year":"2013","journal-title":"Sci Transl Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1136\/annrheumdis-2012-202986","article-title":"Regulatory B cells in ANCA-associated vasculitis","volume":"72","author":"Wilde","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/bjd.13192","article-title":"Impaired function of CD19(+) CD24(hi) CD38(hi) regulatory B cells in patients with pemphigus","volume":"172","author":"Zhu","year":"2015","journal-title":"Br J Dermatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/rheumatology\/kev331","article-title":"Decreased levels of regulatory B cells in patients with systemic sclerosis: association with autoantibody production and disease activity","volume":"55","author":"Matsushita","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"175ra30","DOI":"10.1126\/scitranslmed.3005166","article-title":"Long-Term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response","volume":"5","author":"Colliou","year":"2013","journal-title":"Sci Transl Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1002\/art.22810","article-title":"Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy","volume":"56","author":"Anolik","year":"2007","journal-title":"Arthritis Rheum"},{"key":"B27","doi-asserted-by":"publisher","first-page":"5982","DOI":"10.4049\/jimmunol.0801859","article-title":"Novel human transitional B cell populations revealed by B cell depletion therapy","volume":"182","author":"Palanichamy","year":"2009","journal-title":"J Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1038\/jid.2008.178","article-title":"B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses","volume":"128","author":"Mouquet","year":"2008","journal-title":"J Invest Dermatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa067752","article-title":"A single cycle of rituximab for the treatment of severe pemphigus","volume":"357","author":"Joly","year":"2007","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood.V100.6.2257","article-title":"Rituximab treatment results in impaired secondary humoral immune responsiveness","volume":"100","author":"van der Kolk","year":"2002","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.4049\/jimmunol.0803773","article-title":"In vivo sensitized and in vitro activated B cells mediate tumor regression in cancer adoptive immunotherapy","volume":"183","author":"Li","year":"2009","journal-title":"J Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1200\/JCO.2010.28.9777","article-title":"Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma","volume":"29","author":"Tarella","year":"2011","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/jid.2014.291","article-title":"Persistence of anti-desmoglein 3 IgG(+) B-cell clones in pemphigus patients over years","volume":"135","author":"Hammers","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1182\/blood-2010-09-305847","article-title":"Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I\/II distinction of anti CD20 antibodies","volume":"118","author":"Niederfellner","year":"2011","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517740641","article-title":"Safety and tolerability of inebilizumab (MEDI-551) an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study","author":"Agius","year":"2017","journal-title":"Mult Scler"},{"key":"B36","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood-2017-06-741058","article-title":"Redirecting T cells to hematological malignancies with bispecific antibodies","volume":"131","author":"Velasquez","year":"2018","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1093\/rheumatology\/ket129","article-title":"Efficacy and safety of epratuzumab in patients with moderate\/severe flaring systemic lupus erythematosus from two randomized, double-blind, placebo-controlled multicentre studies (ALLEVIATE) and follow-up","volume":"52","author":"Wallace","year":"2013","journal-title":"Rheumatology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/art.37818","article-title":"CD22 ligation inhibits downstream B cell receptor signaling and downstream Ca2+ flux upon activation","volume":"65","author":"Sieger","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B39","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1136\/annrheumdis-2012-202760","article-title":"Efficacy and safety of eprazumab in patients with moderate\/severe active systemic lupus erythematous: results from EMBLEM, a phase IIb, randomized, double-blind, placebo-controlled, multicentre study","volume":"73","author":"Wallace","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B40","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1172\/JCI117349","article-title":"Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus","volume":"94","author":"Amagai","year":"1994","journal-title":"J Clin Invest"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1038\/sj.jid.5700790","article-title":"Targeting pemphigus autoantibodies through their heavy-chain variable region genes","volume":"127","author":"Payne","year":"2007","journal-title":"J Invest Dermatol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"B44","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1182\/blood-2011-12-397919","article-title":"Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice","volume":"119","author":"Kil","year":"2012","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","article-title":"Ibrutinib for chronic graft versus host disease after failure of prior therapy","volume":"130","author":"Miklos","year":"2017","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2018.00622\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T13:37:08Z","timestamp":1571146628000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2018.00622\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,13]]},"references-count":45,"alternative-id":["10.3389\/fimmu.2018.00622"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.00622","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733133138.793549769","asserted-by":"object"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,13]]},"article-number":"622"}}